Biobeat Technologies Ltd.
10
2
2
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring (ABPM)
Role: lead
Comparison of Non-Invasive Blood Pressure (NIBP) Using the Biobeat Device with an Invasive Arterial Line Catheter
Role: lead
Comparing Cardiac Output Measurements Using a Wearable, Wireless, Non-invasive PPG-Based Device to a Swan Ganz Catheter
Role: lead
Early Warning of Intradialytic Hypotension in Hemodialysis Patients
Role: lead
Relation of Non-invasively Measured Parameters to Clinical Outcomes in CHF Patients
Role: lead
Monitoring Patients With Acute Cardiac Disease Using a Wireless, Wearable, Non-invasive Monitor
Role: lead
Comparing the PiCCO Monitor to the Non-invasive Biobeat (BB)-316PW in ICU Patients
Role: lead
Early Identification of Clinical Deterioration Using a Wearable Monitoring Device
Role: lead
Comparing PPG-based Blood Pressure Measurement to the Gold Standard Manometer
Role: lead
Comparison of the Non-invasive Biobeat Device With an Invasive Arterial Line
Role: lead
All 10 trials loaded